Oceania · Regional markets · Stockhead

Healthcare Quarterly Wrap: These biotechs are pushing for Phase 3 progress

Published by Stockhead · Australia 2 h ago

Alterity has FDA agreement on ATH434’s pivotal trial design, while Recce has revised its Australian study and signed an Australia ... Read More The post Healthcare Quarterly Wrap:…

Read the full article on Stockhead Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (stockhead.com.au)

Also worth reading

ABC Business

Further links between CLP and gas firm emerge as ex-staffer's shares revealed

Business News (WA)

NXT TEC and its directors lose $2m investor dispute

Startup Daily

Canva doubles down with OpenAI just days after launching its 2nd in-house AI model

SmartCompany

Interest rates hit 18-year-high as RBA hikes to 4.85%

Money Magazine

Cash rate hits highest level in 18 years

Fat Tail Daily